Cystic Changes in Hepatic Metastases from Gastrointestinal Stromal Tumors  (GISTs) Treated with Gleevec (Imatinib Mesylate)

Chen, Michael Y. M.; Bechtold, Robert E.; Savage, Paul

doi:10.2214/ajr.179.4.1791059

Cited by 111 publications

(60 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The retroperitoneal region is a rare localization of cystic lymphangiomas, however, it should be included in the differential diagnosis of cystic lesions (Tables I-III) (18)(19)(20)(21)(22)(23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33). The recommended treatment for retroperitoneal cystic masses is complete surgical excision, as a partial resection is associated with increased rates of recurrence.…”

Section: Discussionmentioning

confidence: 99%

Retroperitoneal lymphangioma: A report of 2 cases and a review of the literature regarding the differential diagnoses of retroperitoneal cystic masses

et al. 2016

View full text Add to dashboard Cite

Abstract. Cystic lymphangioma is a type of benign tumor originating from the lymph vessels. The tumor commonly occurs in childhood, in the head or neck regions, and retroperitoneal localization and presentations in adulthood are rare. Determining a pre-operative diagnosis is often challenging, and in the majority of cases, a diagnosis is only possible subsequent to the histological examination of the surgical specimen. A radical resection is the recommended treatment for cystic lymphangioma, and recurrence is usually due to an incomplete excision of the mass. The present study reports 2 cases of cystic lymphangioma, localized in the pancreatic gland and duodenal wall respectively, which were treated with surgical resection. The study also briefly reviews the literature regarding the differential diagnosis of retroperitoneal cystic masses.

show abstract

Section: Discussionmentioning

confidence: 99%

Retroperitoneal lymphangioma: A report of 2 cases and a review of the literature regarding the differential diagnoses of retroperitoneal cystic masses

et al. 2016

View full text Add to dashboard Cite

show abstract

“…These criteria were originally designed to evaluate cytotoxic drugs, which have a different mechanism of action from targeted agents. Targeted agents induce changes in the tumor structure, such as decreased tumor vascularity, decreased density, or necrosis, which are consistent with a therapeutic response, but which may not be accompanied by a change in tumor volume (13). When changes in tumor volume occur, it tends to be some time after the start of treatment.…”

Section: Discussionmentioning

confidence: 99%

Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography

Lassau

Koscielny

Albigès

et al. 2010

Clinical Cancer Research

169

116

View full text Add to dashboard Cite

Purpose: To determine the utility of dynamic contrast-enhanced ultrasonography (DCE-US) as a prognostic tool for metastatic renal cell carcinoma patients receiving sunitinib and to identify DCE-US parameters that correlate with early treatment response.Experimental Design: Thirty-eight patients received 50 mg/d sunitinib on schedule 4/2 (4 weeks on followed by 2 weeks off treatment). After two cycles, response evaluation criteria in solid tumors were used to classify patients as responders or nonresponders. DCE-US evaluations were done before treatment and at day 15; variations between days 0 and 15 were calculated for seven DCE-US functional parameters and were compared for responders and nonresponders. The correlation between DCE-US parameters and disease-free survival (DFS) and overall survival (OS) was assessed.Results: The ratio between DCE-US examinations at baseline and day 15 significantly correlated with response in five of the seven DCE-US parameters. Two DCE-US parameters (time to peak intensity and slope of the wash-in) were significantly associated with DFS; time to peak intensity was also significantly associated with OS.Conclusions: DCE-US is a useful tool for predicting the early efficacy of sunitinib in metastatic renal cell carcinoma patients. Robust correlations were observed between functional parameters and classic assessments, including DFS and OS. Clin Cancer Res; 16(4); 1216-25. ©2010 AACR.

show abstract

“…Highly vascularized tumors are generally larger than tumors with no arterial vascularization (26). There is some evidence to suggest that targeted therapies can induce changes in tumor structure (e.g., by decreasing tumor vascularity or inducing necrosis), consistent with a therapeutic response, before a change in tumor size or volume is observed (27,28). Furthermore, changes in tumor vascularization can be predictive of subsequent changes in tumor volume (29,30).…”

mentioning

confidence: 99%

Phase I Trial of Sorafenib in Combination with IFN α-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma

Escudier

Lassau

Angevin

et al. 2007

Clinical Cancer Research

135

View full text Add to dashboard Cite

Purpose: To determine the safety, maximum tolerated dose, pharmacokinetics, and efficacy, and to evaluate biomarkers, of the multikinase inhibitor sorafenib plus IFN a-2a in advanced renal cell carcinoma (RCC) or melanoma. Experimental Design: Patients received 28-day cycles of continuous, oral sorafenib twice daily and s.c. IFN thrice weekly: sorafenib 200 mg twice daily plus IFN 6 million IU (MIU) thrice weekly (cohort1); and sorafenib 400 mg twice daily plus IFN 6 MIU thrice weekly (cohort 2); or plus IFN 9 MIU thrice weekly (cohort 3). Tumor response was assessed by Response Evaluation Criteria in Solid Tumors and dynamic contrast-enhanced ultrasonography. Results: Thirteen patients received at least one dose of sorafenib plus IFN (12 RCC; one melanoma). The maximum tolerated dose was not reached [only one dose-limiting toxicity (grade 3 asthenia)]. Most frequently reported drug-related adverse events were grade 2 or less in severity, including fatigue, diarrhea, nausea, alopecia, and hand-foot skin reaction. One (7.7%) RCC patient achieved partial response and eight (61.5%) had stable disease (including the melanoma patient). Good responders assessed by dynamic contrast-enhanced ultrasonography had increased progression-free survival and overall survival, relative to poor responders. IFN had no effect on the pharmacokinetics of sorafenib. There were no significant changes in absolute values of lymphocytes, levels of proangiogenic cytokines, or inhibition of phosphorylated extracellular signalregulated kinase inTcells or natural killer cells, with combination therapy. Conclusions: This sorafenib combination was well tolerated, with preliminary antitumor activity in advanced RCC and melanoma patients. There were no drug-drug interactions and the recommended dose for future studies is sorafenib 400 mg twice daily plus IFN 9 MIU.Renal cell carcinoma (RCC) and melanoma have poor prognoses when diagnosed in advanced stages (1), and are associated with a median survival of V12 months (2, 3). RCC accounts for 80% to 95% of kidney tumors, and f30% of RCC patients have metastatic disease at diagnosis (1, 4, 5).The Raf/extracellular signal-regulated kinase (ERK) kinase (MEK)/ERK signaling pathway, which regulates cell proliferation and survival (6), is implicated in the onset and development of RCC (7) and melanoma (6). Overactivation of Raf-1 is detected in 55% of RCC biopsies in the absence of oncogenic ras/raf mutations (7). Clear cell carcinomas, which account for 75% to 85% of renal tumors, are characterized by loss of the von Hippel-Lindau tumor-suppressor gene (8), leading to overexpression of proangiogenic vascular endothelial growth factor (VEGF) and platelet-derived growth factor-h (9, 10). Activating b-raf mutations occur in >60% of melanomas, of which f90% are V600E (11, 12). The V600E b-raf mutant is constitutively active and implicated in tumor development (12). Inhibiting Raf/MEK/ERK signaling induces apoptosis in melanoma cells, but not in normal melanocytes, suggesting that oncogenic b-raf ma...

show abstract

Cystic Changes in Hepatic Metastases from Gastrointestinal Stromal Tumors (GISTs) Treated with Gleevec (Imatinib Mesylate)

Cited by 111 publications

References 8 publications

Retroperitoneal lymphangioma: A report of 2 cases and a review of the literature regarding the differential diagnoses of retroperitoneal cystic masses

Retroperitoneal lymphangioma: A report of 2 cases and a review of the literature regarding the differential diagnoses of retroperitoneal cystic masses

Metastatic Renal Cell Carcinoma Treated with Sunitinib: Early Evaluation of Treatment Response Using Dynamic Contrast-Enhanced Ultrasonography

Phase I Trial of Sorafenib in Combination with IFN α-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma

Contact Info

Product

Resources

About